Comparison of Ximelagatran with Warfarin for the Prevention of Venous Thromboembolism after Total Knee Replacement

New England Journal of Medicine

Volumn 349, Issue 18, 2003, Pages 1703-1712

  Francis, Charles W ^a   Berkowitz, Scott D ^b   Comp, Philip C ^c   Lieberman, Jay R ^d   Ginsberg, Jeffrey S ^e   Paiement, Guy ^f   Peters, Gary R ^b   Roth, Anne W ^b   McElhattan, Jennifer ^b   Colwell Jr , Clifford W ^g  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MCMASTER UNIVERSITY   (Canada)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g SCRIPPS CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; INTERNATIONAL STANDARD UNIT; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHLEBOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SURGICAL WOUND; THROMBOEMBOLISM; TOTAL KNEE REPLACEMENT;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, KNEE; AZETIDINES; BENZYLAMINES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PRODRUGS; PULMONARY EMBOLISM; THROMBOEMBOLISM; TREATMENT OUTCOME; VENOUS THROMBOSIS; WARFARIN;

EID: 0142151552     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa035162     Document Type: Article

References (34)

1. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001;119:Suppl 1:132S-175S.
2. Stulberg BN, Insall JN, Williams GW, Ghelman B. Deep-vein thrombosis following total knee replacement: an analysis of six hundred and thirty-eight arthroplasties. J Bone Joint Surg Am 1984;66:194-201.
3. Stringer MD, Steadman CA, Hedges AR, Morley TR, Kakkar VV. Deep vein thrombosis after elective knee surgery: an incidence study in 312 patients. J Bone Joint Surg Br 1989; 71:492-7.
4. Mohr DN, Silverstein MD, Ilstrup DM, Heit JA, Morrey BF. Venous thromboembolism associated with hip and knee arthroplasty: current prophylactic practices and outcomes. Mayo Clin Proc 1992;67:861-70.
5. Khaw FM, Moran GG, Pinder IM, Smith IR. The incidence of fatal pulmonary embolism after knee replacement with no prophylactic anticoagulation. J Bone Joint Surg Br 1993;75:940-1.
6. Ansari S, Warwick D, Ackroyd CE, Newman JH. Incidence of fatal pulmonary embolism after 1,390 knee arthroplasties without routine prophylactic anticoagulation, except in high-risk cases. J Arthroplasty 1997;12:599-602.
7. Klement P, Garlsson S, Rak J, et al. The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model. J Thromb Haemost 2003;1:587-94.
8. Johansson LC, Frison L, Logren U, Fager G, Gustafsson D, Eriksson UG. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet 2003;42:381-92.
9. Eriksson UG, Johansson L, Frison L, et al. Pharmacokinetics (PK) of melagatran (M) in young and elderly healthy subjects and orthopaedic surgery patients. Clin Pharmacol Ther 2001;69(2):P24. abstract.
10. Eriksson UG, Fager G, Eriksson-Lepkowska M, et al. Effect of acetylsalicylic acid (ASA) on the pharmacodynamics and pharmacokinetics (PK) of melagatran (M), active form of the oral direct thrombin inhibitor, H 376/95. Clin Pharmacol Ther 2001;69(2): P24. abstract.
11. Eriksson-Lepkowska M, Thuresson A, Bylock A, Frison L, Eriksson UG. The effect of the oral direct thrombin inhibitor, ximelagatran (pINN, formerly H 376/95), on the pharmacokinetics of diazepam in healthy male volunteers. In: Proceedings of the 28th Congress of the International Society on Thrombosis and Haemostasis, Paris, July 6-12, 2001. abstract.
12. Idem. The effect of the oral direct thrombin inhibitor, ximelagatran (pINN, formerly H 376/95), on the pharmacokinetics and pharmacodynamics of diclofenac in healthy male volunteers. In: Proceedings of the 28th Congress of the International Society on Thrombosis and Haemostasis, Paris, July 6-12, 2001. abstract.
13. Johnasson S, Bylock A, Eriksson-Lepkowska M, Thuresson A, Frison L, Eriksson UG. The effect of the oral direct thrombin inhibitor, ximelagatran (pINN, formerly H 376/95), on the pharmacokinetics of nifedipine in healthy male volunteers. In: Proceedings of the 28th Congress of the International Society on Thrombosis and Haemostasis, Paris, July 6-12, 2001. abstract.
14. Francis CW, Davidson BL, Berkowitz SD, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind trial. Ann Intern Med 2002; 137:648-55.
15. Heit JA, Colwell CW, Francis CW, et al. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med 2001;161:2215-21.
16. Eriksson BI, Agnelli G, Cohen AT, et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 2003;89:288-96.
17. Eriksson BI, Bergqvist D, Kälebo P, et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or total knee replacement: the METHRO II randomised trial. Lancet 2002;360:1441-7.
18. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
19. Rabinov K, Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg 1972;104:134-44.
20. Kälebo P, Ekman S, Lindbratt S, et al. Percentage of inadequate phlebograms and observer agreement in thromboprophylactic multicenter trials using standardized methodology and central assessment. Thromb Haemost 1996;76:893-6.
21. Cohen AT, Bailey CS, Alikhan R, Cooper DJ. Extended thromboprophylaxis with low molecular weight heparin reduces symptomatic venous thromboembolism following lower limb arthroplasty - a meta-analysis. Thromb Haemost 2001;85:940-1.
22. RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty: the RD Heparin Arthroplasty Group. J Bone Joint Surg Am 1994;76:1174-85.
23. Heit JA, Berkowitz SD, Bona R, et al. Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind, dose-ranging study. Thromb Haemost 1997;77:32-8.
24. Fitzgerald RH Jr, Spiro TE, Trowbridge AA, et al. Prevention of venous thromboembolic disease following primary total knee arthroplasty: a randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. J Bone Joint Surg Am 2001;83:900-6.
25. Hull K, Raskob G, Pineo G, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993;329:1370-6.
26. Hamulyak K, Lensing AWA, van der Meer J, Smid WM, van Ooy A, Hoek A. Subcutaneous low-molecular-weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Thromb Haemost 1995;74: 1428-31.
27. Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of venous thromboembolism after knee arthroplasty: a randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med 1996;124:619-26.
28. Francis CW, Pellegrini VD Jr, Leibert KM, et al. Comparison of two warfarin regimens in the prevention of venous thrombosis following total knee replacement. Thromb Haemost 1996;75:706-11.
29. Bauer KA, Eriksson BI, Lassen MR, Turpie AGG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001;345:1305-10.
30. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002;162:1833-40.
31. Mesko JW, Brand RA, Iorio R, et al. Venous thromboembolic disease management patterns in total hip arthroplasty and total knee arthroplasty patients: a survey of the AAHKS membership. J Arthroplasty 2001;16:679-88.
32. Gross M, Anderson DR, Nagpal S, O'Brien B. Venous thromboembolism prophylaxis after total hip or knee arthroplasty: a survey of Canadian orthopedic surgeons. Can J Surg 1999;42:457-61.
33. Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119:Suppl 1:8S-21S.
34. Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. Chest 2001; 119:Suppl 1:22S-38S.